Other prokinetics vs domperidone: Not symptom‐free or no symptom improvement
It is very uncertain whether other prokinetics changes not symptom‐free or no symptoms improvement (itopride 50 three times… compared with domperidone 10mg three times a day (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Other prokinetics vs domperidone 10mg three times a day Not symptom‐free or no symptoms improvement (itopride 50 three times per day, cinitapride 1 mg three times per day, mosapride 5 mg three times per day versus domperidone 10 mg three times per day) · functional dyspepsia It is very uncertain whether other prokinetics changes not symptom‐free or no symptoms improvement (itopride 50 three times… compared with domperidone 10mg three times a day (very low certainty). Prokinetics for functional dyspepsia (2018) · Cochrane Headline outcomes only | RR 0.94 [0.83, 1.07] | 7 studies · 1527 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Prokinetics for functional dyspepsia 2018 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.